Oral GLP-1 pill (Foundayo)
Orforglipron (Foundayo) is the first oral GLP-1, a once-daily pill taken any time of day with no food or water restrictions. Set your start date and current step to project the earliest dates the label allows you to move up the six-step monthly titration.
Each row shows the earliest date the label permits this dose (a minimum time at the step before it). It is not a recommendation to advance; your prescriber decides whether and when to move up.
| Step | Dose | Earliest start | Min duration |
|---|---|---|---|
| Month 1 (start)current | 0.8 mg | Jun 13, 2026 | 30 days |
| Month 2 | 2.5 mg | Jul 13, 2026 | 30 days |
| Month 3 | 5.5 mg | Aug 12, 2026 | 30 days |
| Month 4 | 9 mg | Sep 11, 2026 | 30 days |
| Month 5 | 14.5 mg | Oct 11, 2026 | 30 days |
| Month 6 (max) | 17.2 mg | Nov 10, 2026 | maintenance |
Informational and educational only. Not medical advice. This tool projects the earliest dates the FDA label permits a dose increase (a minimum time at each step). It does not recommend whether or when to change your dose. Follow your prescriber.
Orforglipron (brand Foundayo, Eli Lilly) is the first oral, non-peptide GLP-1 receptor agonist, approved by the FDA on April 1, 2026 for chronic weight management in adults with obesity, or overweight with a weight-related condition. It is a once-daily tablet that, unlike oral semaglutide, can be taken at any time of day with no food or water restrictions. Its plasma elimination half-life is long, approximately 29 to 49 hours after an oral dose per the prescribing information, so blood levels accumulate over about the first week of daily dosing before reaching steady state. The approved dose is titrated monthly to reduce gastrointestinal side effects: 0.8 mg to start, then 2.5, 5.5, 9, 14.5, and a maximum of 17.2 mg once daily, with at least about 30 days at each step. The curve shown here illustrates that daily accumulation to steady state using a representative half-life and is not individualized. This calculator performs math on the values you enter and does not recommend any dose. Consult a licensed clinician.
Orforglipron, sold as Foundayo by Eli Lilly, is the first oral GLP-1 receptor agonist: a once-daily pill approved by the FDA on April 1, 2026 for chronic weight management. Unlike oral semaglutide, it can be taken any time of day with no food or water restrictions. It is dosed by a monthly titration from 0.8 mg up to a maximum of 17.2 mg.
The approved schedule starts at 0.8 mg once daily and increases monthly, with at least about 30 days at each step: 0.8 mg, then 2.5, 5.5, 9, 14.5, and a maximum of 17.2 mg. Maintenance can be 5.5, 9, 14.5, or 17.2 mg depending on response and tolerability. Set your start date above to see the earliest dates the label allows each increase. This tool does not recommend whether to advance; your prescriber decides.
No special timing is required. Foundayo can be taken at any time of day, with or without food, and does not require the fasting and water rules that oral semaglutide does. Follow the directions on your prescription.
Its elimination half-life is long, approximately 29 to 49 hours after an oral dose according to the prescribing information. Because of this, blood levels build up over about the first week of once-daily dosing before leveling off at steady state.
Yes. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with a weight-related medical problem. It is a prescription medication; this tool does not recommend any dose or use. Consult a licensed clinician.
Orforglipron is a non-peptide GLP-1 receptor agonist. It activates the GLP-1 receptor, the same target as injectable GLP-1 medicines, which slows stomach emptying and reduces appetite so you tend to eat less. Because it is a small molecule rather than a peptide, it survives digestion, which is what lets it work as a daily pill instead of an injection.
Per the Foundayo prescribing information, the most common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, and indigestion, which is why the dose is raised slowly month by month. At the 17.2 mg dose the label reports nausea in about 35 percent of patients, diarrhea in about 25 percent, constipation in about 24 percent, and vomiting in about 24 percent. Like other GLP-1 medicines, Foundayo carries a boxed warning about thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. This is not a complete list of side effects; read the prescribing information and talk with your clinician.
Yes. Orforglipron (Foundayo) was approved by the FDA on April 1, 2026 and is a prescription medication supplied as bottles of 30 tablets in each of the six strengths. Whether it is in stock and what it costs depend on your pharmacy and insurance. This tool does not provide pricing or recommend a dose; ask your prescriber or pharmacy.
Source: Foundayo (orforglipron) Prescribing Information · How we calculate